These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 24603946)

  • 1. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
    Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
    J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
    Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
    J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive Immunotherapy Targeting Tau Oligomeric Strains Reverses Tauopathy Phenotypes in Aged Human-Tau Mice in a Mouse Model-Specific Manner.
    Bittar A; Al-Lahham R; Bhatt N; Moore K; Montalbano M; Jerez C; Fung L; McAllen S; Ellsworth A; Kayed R
    J Alzheimers Dis; 2022; 90(3):1103-1122. PubMed ID: 36189593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
    Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
    J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice.
    Gerson J; Castillo-Carranza DL; Sengupta U; Bodani R; Prough DS; DeWitt DS; Hawkins BE; Kayed R
    J Neurotrauma; 2016 Nov; 33(22):2034-2043. PubMed ID: 26729399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
    Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
    Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
    Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligomeric tau-targeted immunotherapy in Tg4510 mice.
    Schroeder S; Joly-Amado A; Soliman A; Sengupta U; Kayed R; Gordon MN; Morgan D
    Alzheimers Res Ther; 2017 Jun; 9(1):46. PubMed ID: 28655349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
    Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
    Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers.
    Umeda T; Ono K; Sakai A; Yamashita M; Mizuguchi M; Klein WL; Yamada M; Mori H; Tomiyama T
    Brain; 2016 May; 139(Pt 5):1568-86. PubMed ID: 27020329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.
    Wheeler JM; McMillan PJ; Hawk M; Iba M; Robinson L; Xu GJ; Dombroski BA; Jeong D; Dichter MA; Juul H; Loomis E; Raskind M; Leverenz JB; Trojanowski JQ; Lee VM; Schellenberg GD; Kraemer BC
    Acta Neuropathol Commun; 2015 Jun; 3():33. PubMed ID: 26041339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.
    Rozenstein-Tsalkovich L; Grigoriadis N; Lourbopoulos A; Nousiopoulou E; Kassis I; Abramsky O; Karussis D; Rosenmann H
    Exp Neurol; 2013 Oct; 248():451-6. PubMed ID: 23876516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
    Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
    Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice.
    Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I
    Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.
    Polydoro M; Acker CM; Duff K; Castillo PE; Davies P
    J Neurosci; 2009 Aug; 29(34):10741-9. PubMed ID: 19710325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.